Latest Interim Results News

Marimaca Copper Corp reported solid liquidity with $25.6 million in working capital and completed a C$24.4 million private placement, while managing ongoing challenges related to the liquidation of a key receivable from Minera Rayrock Ltda.

Oneview Healthcare PLC reported a 36% increase in revenue for the first half of 2025, driven by strong deployment activity and new US customers, while managing a wider net loss due to FX impacts and restructuring costs.

Amplia Therapeutics reports encouraging interim results from its ACCENT trial, with its drug narmafotinib improving progression-free survival and response rates in advanced pancreatic cancer.

Telix Pharmaceuticals has recast its historical financials from AUD to USD to better reflect its US-centric revenue streams and reports increased operating expenditure tied to recent acquisitions and growth initiatives.

Avecho Biotechnology reports strong progress in its Phase III clinical trial for a CBD-based insomnia treatment, with recruitment accelerating across multiple Australian sites and interim results expected early next year.

Amplia Therapeutics has launched a $27.5 million capital raising to advance its lead drug Narmafotinib, a promising FAK inhibitor showing superior efficacy in pancreatic cancer trials. The funds will support ongoing and new clinical studies, positioning the company for pivotal regulatory milestones.

Paradigm Biopharmaceuticals has locked in a $27 million USD convertible note facility to fully fund its pivotal Phase 3 trial for knee osteoarthritis, ensuring operational momentum through key clinical milestones.

GPT Group has announced an estimated distribution of 12.0 cents per stapled security for the first half of 2025, setting the stage ahead of its interim results release in August.

Orthocell’s new study confirms Remplir™ delivers superior nerve regeneration and faster muscle recovery compared to traditional sutures, bolstering its US market rollout plans.

Syntara Limited has unveiled encouraging interim Phase 2a data for SNT-5505, an add-on therapy targeting myelofibrosis patients with suboptimal response to ruxolitinib. The data highlight meaningful symptom relief and spleen volume reduction, positioning the drug as a potential game-changer in a challenging treatment landscape.

Syntara Limited reports encouraging interim Phase 2 data for its drug SNT-5505 combined with ruxolitinib, demonstrating significant symptom relief and spleen volume reduction in myelofibrosis patients. The company plans to engage the FDA soon to discuss pivotal trial design.

Syntara Limited is set to reveal fresh interim results from its Phase 2 trial of SNT-5505, targeting myelofibrosis, during an investor webinar ahead of a major European hematology conference.